Skip to content
How It Works
Explore
Ask a Question Resources Pricing
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Sign Up
PubMed This is a summary of 20 peer-reviewed journal articles Updated
Endocrinology · Type A Insulin Resistance Syndrome

Treatment Strategies: Balancing Blood Sugar and Hormones

At a Glance

Type A Insulin Resistance Syndrome requires individualized specialist care because a genetic problem with insulin receptors can cause severe insulin resistance and dangerous blood sugar drops. Treatment may combine carefully adjusted medicines, hormone therapy, nutrition, and glucose monitoring.

Managing Type A Insulin Resistance Syndrome (TAIRS) requires a highly personalized strategy. Because the underlying problem is a genetic defect in the insulin receptor, treatments that work for common Type 2 diabetes often need to be adjusted or swapped for specialized approaches [1]. The goal of treatment is to stabilize blood sugar swings, reduce high insulin levels, and manage hormonal symptoms [2].

Glycemic Control: Managing the Highs and Lows

There is no single “standard” medication for TAIRS, but several classes are used to help the body process sugar more effectively [3].

Insulin Therapy

In many forms of diabetes, doctors add insulin to overcome resistance. In TAIRS, because the receptors are genetically impaired [4], the response to injected insulin can be blunted [1]. However, insulin can still be a necessary and highly effective treatment when TAIRS causes diabetes, sometimes requiring very high doses under specialist supervision. Dosing must be carefully individualized to balance lowering blood sugar against the risk of severe hypoglycemic crashes [5][6]. Never stop or escalate your insulin without the guidance of your prescribing team.

Oral Medications

  • Metformin: This is often the first medication tried. It can improve menstrual regularity and skin symptoms in some patients [7]. However, some patients continue to experience post-meal blood sugar crashes while taking it, so careful monitoring is needed [6].
  • SGLT2 Inhibitors: These medications (like empagliflozin) work by helping the kidneys flush excess sugar out through urine [3]. While there is limited off-label evidence for their use in TAIRS, they carry a specific risk of euglycemic diabetic ketoacidosis—a serious condition where your blood becomes acidic even if your sugar levels look normal—especially during fasting, dehydration, acute illness, or reduced insulin [8][9]. They also increase the risk of genital infections.
  • Pioglitazone: This medication helps “sensitize” the body to insulin. While it has shown promise in some case reports for lowering blood sugar and androgens, it is usually used as part of a combination therapy and can cause edema, weight gain, and worsen heart failure [10].

Managing Hormonal Symptoms (Hyperandrogenism)

The high insulin levels in TAIRS often cause the ovaries to overproduce androgens, leading to hair growth (hirsutism), acne, and missed periods [2].

  • Anti-Androgens: Medications like spironolactone or flutamide can help block the effects of male hormones on the skin and hair follicles [10][6]. Note that spironolactone requires strict attention to potassium, kidney function, and pregnancy precautions. Flutamide carries potentially severe liver toxicity risks.
  • Hormonal Regulation: Combined oral contraceptives (birth control pills) may be used to regulate menstrual cycles and protect the lining of the uterus, though your doctor will assess your individual risk for blood clots before prescribing them [11][12].
  • GnRH Agonists: In severe cases where other treatments fail, these medications can be used to “reset” the hormonal signal from the brain to the ovaries, which can significantly reduce androgen levels [13]. These can cause hypoestrogenic symptoms and bone loss.

Specialized and Emerging Therapies

For the most severe cases of TAIRS that do not respond to oral medications or insulin, specialists may consider rhIGF-1 (mecasermin) [14]. This is a lab-made version of a growth factor that can bypass the impaired insulin receptor to lower blood sugar [15]. Because it is generally an off-label specialist treatment that carries a risk of serious hypoglycemia and other adverse effects, it is generally reserved for patients with extreme, refractory insulin resistance [16][17].

The Role of Medical Nutrition Therapy

Diet is a supportive component of managing the “dual nature” of blood sugar in TAIRS, though it cannot correct the genetic defect.

  • Low-Glycemic Index (Low-GI) Foods: Choosing carbohydrates that digest slowly (like beans, lentils, and whole grains) can help stabilize insulin “spikes” and later “crashes” [18][19].
  • Preventing Hypoglycemia: Some patients find relief by eating smaller, more frequent meals. In highly specific situations, specialists may use specialized dosing of uncooked cornstarch to provide a slow-release glucose source [5]. Uncooked cornstarch is not a universal self-treatment and should only be considered under the direction of an endocrinologist and experienced dietitian.

Because TAIRS is so rare, your treatment plan will likely change over time as you and your care team learn how your body responds to different strategies [20]. Monitoring your blood sugar patterns with a Continuous Glucose Monitor (CGM) can provide the data needed to make these adjustments safely [18].

Common questions in this guide

What treatments are used for Type A Insulin Resistance Syndrome?
Treatment is individualized because the insulin receptor does not respond normally, so common type 2 diabetes approaches may need adjustment. Options may include carefully supervised insulin, metformin or other medicines, hormone treatment, nutrition therapy, and continuous glucose monitoring.
Can insulin help if I have TAIRS, and is it safe?
Insulin can lower blood sugar in TAIRS and may be necessary when diabetes develops, sometimes at very high doses. Because blood sugar can fall dangerously low, the dose must be individualized and changed only with the prescribing team’s guidance.
What should I know about SGLT2 inhibitors with TAIRS?
SGLT2 inhibitors have limited off-label evidence in TAIRS and can cause euglycemic diabetic ketoacidosis, in which the blood becomes acidic even when glucose looks normal. The risk is higher during fasting, dehydration, illness, or reduced insulin, so patients need a clinician-provided sick-day and ketone-testing plan.
How can TAIRS-related excess hair and irregular periods be treated?
Options may include anti-androgens, combined oral contraceptives, or, in severe cases, a GnRH agonist. Spironolactone requires attention to potassium, kidney function, and pregnancy precautions; other treatments also have risks that your clinician should review.
When is rhIGF-1 used for Type A Insulin Resistance Syndrome?
Specialists may consider rhIGF-1, also called mecasermin, when extreme insulin resistance does not respond to usual medicines or insulin. It is generally an off-label treatment and can cause serious hypoglycemia and other adverse effects, so it requires specialist supervision.
Can diet help prevent blood sugar crashes in TAIRS?
Low-glycemic foods and, for some people, smaller meals more often may help reduce rapid rises and later drops in blood sugar. Uncooked cornstarch is not a general self-treatment and should be used only if an endocrinologist and experienced dietitian recommend a specific plan.
Why might a continuous glucose monitor help with TAIRS treatment?
A continuous glucose monitor records blood sugar patterns, including after-meal rises and lows, which can help the care team adjust treatment more safely. It does not correct the genetic insulin-receptor problem, but it can provide useful information for ongoing management.

Get notified when new evidence is published on Insulin-resistance syndrome type A.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

References

References (20)
  1. 1

    Long-term efficacy of the sodium-glucose cotransporter 2 inhibitor, ipragliflozin, in a case of type A insulin resistance syndrome.

    Nagashima S, Wakabayashi T, Saito N, et al.

    Journal of diabetes investigation 2020; (11(5)):1363-1365 doi:10.1111/jdi.13241.

    PMID: 32100949
  2. 2

    Type A insulin resistance syndrome misdiagnosed as polycystic ovary syndrome: a case report.

    Lin L, Chen C, Fang T, et al.

    Journal of medical case reports 2019; (13(1)):347 doi:10.1186/s13256-019-2304-4.

    PMID: 31771632
  3. 3

    A Multicenter, Open-Label, Single-Arm Trial of the Efficacy and Safety of Empagliflozin Treatment for Refractory Diabetes Mellitus with Insulin Resistance (EMPIRE-01).

    Hirota Y, Kakei Y, Imai J, et al.

    Diabetes therapy : research, treatment and education of diabetes and related disorders 2024; (15(2)):533-545 doi:10.1007/s13300-023-01526-x.

    PMID: 38216831
  4. 4

    Severe insulin resistance in disguise: A familial case of reactive hypoglycemia associated with a novel heterozygous INSR mutation.

    Innaurato S, Brierley GV, Grasso V, et al.

    Pediatric diabetes 2018; (19(4)):670-674 doi:10.1111/pedi.12632.

    PMID: 29411486
  5. 5

    Unusual Glycemic Presentations in a Child with a Novel Heterozygous Intragenic INSR Deletion.

    Verdecchia F, Akcan N, Dastamani A, et al.

    Hormone research in paediatrics 2020; (93(6)):396-401 doi:10.1159/000510462.

    PMID: 33040071
  6. 6

    Diagnostic and management challenges from childhood, puberty through to transition in severe insulin resistance due to insulin receptor mutations.

    Wei C, Burren CP

    Pediatric diabetes 2017; (18(8)):835-838 doi:10.1111/pedi.12486.

    PMID: 28093873
  7. 7

    A New Mutation of the INSR Gene in a 13-Year-Old Girl with Severe Insulin Resistance Syndrome in China.

    Jin J, Liang X, Wei J, Xu L

    BioMed research international 2021; (2021()):8878149 doi:10.1155/2021/8878149.

    PMID: 33728347
  8. 8

    Case report: A case of Rabson-Mendenhall syndrome: long-term follow-up and therapeutic management with empagliflozin.

    Foglino R, Barbetti F, Morotti E, et al.

    Frontiers in genetics 2024; (15()):1414451 doi:10.3389/fgene.2024.1414451.

    PMID: 38978877
  9. 9

    A multicenter, open-label, single-arm trial of the long-term safety of empagliflozin treatment for refractory diabetes mellitus with insulin resistance (EMPIRE-02).

    Hirota Y, Kakei Y, Imai J, et al.

    Journal of diabetes investigation 2024; (15(9)):1211-1219 doi:10.1111/jdi.14226.

    PMID: 38702973
  10. 10

    Treatment and five-year follow-up of type A insulin resistance syndrome: A case report.

    Chen YH, Chen QQ, Wang CL

    World journal of clinical cases 2022; (10(8)):2522-2528 doi:10.12998/wjcc.v10.i8.2522.

    PMID: 35434067
  11. 11

    The Diagnosis of Polycystic Ovary Syndrome in Adolescents.

    Rosenfield RL

    Pediatrics 2015; (136(6)):1154-65 doi:10.1542/peds.2015-1430.

    PMID: 26598450
  12. 12

    Clinical, hormonal and metabolic parameters in women with PCOS with different combined oral contraceptives (containing chlormadinone acetate versus drospirenone).

    Podfigurna A, Meczekalski B, Petraglia F, Luisi S

    Journal of endocrinological investigation 2020; (43(4)):483-492 doi:10.1007/s40618-019-01133-3.

    PMID: 31654312
  13. 13

    GnRH Agonist Improves Hyperandrogenism in an Adolescent Girl With an Insulin Receptor Gene Mutation.

    Paprocki E, Barral RL, Vanden Brink H, et al.

    Journal of the Endocrine Society 2019; (3(6)):1196-1200 doi:10.1210/js.2019-00045.

    PMID: 31187077
  14. 14

    Mecasermin in Insulin Receptor-Related Severe Insulin Resistance Syndromes: Case Report and Review of the Literature.

    Plamper M, Gohlke B, Schreiner F, Woelfle J

    International journal of molecular sciences 2018; (19(5)) doi:10.3390/ijms19051268.

    PMID: 29695048
  15. 15

    Successful rhIGF1 treatment for over 5 years in a patient with severe insulin resistance due to homozygous insulin receptor mutation.

    Carmody D, Ladsaria SS, Buikema RK, et al.

    Diabetic medicine : a journal of the British Diabetic Association 2016; (33(3)):e8-e12 doi:10.1111/dme.12884.

    PMID: 26262567
  16. 16

    [Donohue syndrome and use of continuous subcutaneous IGF1 pump therapy].

    Melikyan MA, Ivannikova TE, Milovanova NV, et al.

    Problemy endokrinologii 2022; (68(5)):79-86 doi:10.14341/probl13121.

    PMID: 36337021
  17. 17

    Clinical spectrum of extreme insulin resistance syndromes treated with rhIGF-1: A single-center experience.

    Improda N, Katugampola H, Cerbone M, et al.

    The Journal of clinical endocrinology and metabolism 2026; (111(7)):2049-2063 doi:10.1210/clinem/dgag031.

    PMID: 41606799
  18. 18

    Diazoxide-unresponsive Hyperinsulinemic Hypoglycaemia in a Preterm Infant with Heterozygous Insulin Receptor Gene Mutation

    Poon SWY, Chung BHY, Wong MSC, Tsang AMC

    Journal of clinical research in pediatric endocrinology 2025; (17(1)):115-119 doi:10.4274/jcrpe.galenos.2023.2022-12-10.

    PMID: 37074094
  19. 19

    Glycemic index, glycemic load and glycemic response: An International Scientific Consensus Summit from the International Carbohydrate Quality Consortium (ICQC).

    Augustin LSA, Kendall CWC, Jenkins DJA, et al.

    Nutrition, metabolism, and cardiovascular diseases : NMCD 2015; (25(9)):795-815 doi:10.1016/j.numecd.2015.05.005.

    PMID: 26160327
  20. 20

    Combination Therapy With Semaglutide and Dapagliflozin as an Effective Approach for the Management of Type A Insulin Resistance Syndrome: A Case Report.

    Martínez-Montoro JI, Pinzón-Martín JL, Damas-Fuentes M, et al.

    Frontiers in endocrinology 2022; (13()):838887 doi:10.3389/fendo.2022.838887.

    PMID: 35498407

This page is for informational purposes only and does not constitute medical advice about your Type A Insulin Resistance Syndrome. Do not change insulin, SGLT2 inhibitors, hormone medicines, or specialized nutrition plans without guidance from your endocrinology team.

Guide contents Insulin-resistance syndrome type A
Research & Literature
04 The Lab Journey 06 The Long View